DK3106150T3 - Forbedrede farmaceutiske sammensætninger af pimobendan - Google Patents

Forbedrede farmaceutiske sammensætninger af pimobendan Download PDF

Info

Publication number
DK3106150T3
DK3106150T3 DK16177625.7T DK16177625T DK3106150T3 DK 3106150 T3 DK3106150 T3 DK 3106150T3 DK 16177625 T DK16177625 T DK 16177625T DK 3106150 T3 DK3106150 T3 DK 3106150T3
Authority
DK
Denmark
Prior art keywords
pimobendan
pharmaceutical compositions
improved pharmaceutical
improved
compositions
Prior art date
Application number
DK16177625.7T
Other languages
English (en)
Inventor
Péter Laczay
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Application granted granted Critical
Publication of DK3106150T3 publication Critical patent/DK3106150T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
DK16177625.7T 2013-12-04 2014-12-01 Forbedrede farmaceutiske sammensætninger af pimobendan DK3106150T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1300702 2013-12-04
EP14824382.7A EP2925305B1 (en) 2013-12-04 2014-12-01 Improved pharmaceutical compositions of pimobendan

Publications (1)

Publication Number Publication Date
DK3106150T3 true DK3106150T3 (da) 2021-11-01

Family

ID=89708176

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14824382.7T DK2925305T3 (da) 2013-12-04 2014-12-01 Forbedrede farmaceutiske sammensætninger af pimobendan.
DK16177625.7T DK3106150T3 (da) 2013-12-04 2014-12-01 Forbedrede farmaceutiske sammensætninger af pimobendan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14824382.7T DK2925305T3 (da) 2013-12-04 2014-12-01 Forbedrede farmaceutiske sammensætninger af pimobendan.

Country Status (15)

Country Link
US (5) US10172804B2 (da)
EP (2) EP3106150B1 (da)
JP (3) JP5905999B2 (da)
KR (1) KR102308973B1 (da)
CN (2) CN105813633B (da)
AU (2) AU2014359427B2 (da)
BR (2) BR112016011111B1 (da)
CA (2) CA3176466A1 (da)
DK (2) DK2925305T3 (da)
EA (2) EA201992230A1 (da)
ES (2) ES2883448T3 (da)
HU (2) HUE032347T2 (da)
MX (1) MX2016007134A (da)
PL (2) PL3106150T3 (da)
WO (1) WO2015082389A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US10398705B2 (en) * 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
HUE054186T2 (hu) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
KR102308973B1 (ko) 2013-12-04 2021-10-08 베링거잉겔하임베트메디카게엠베하 개선된 피모벤단의 약제학적 조성물
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP3257574A1 (en) * 2016-06-15 2017-12-20 Clariant International Ltd Method for producing a particle-shaped material
KR20210114978A (ko) * 2019-02-20 2021-09-24 조에티스 서비시즈 엘엘씨 맛이 좋은 제형
WO2021081366A1 (en) * 2019-10-23 2021-04-29 Piedmont Animal Health Inc. Pimobendan formulation and method of use thereof
RU2762989C1 (ru) * 2020-09-28 2021-12-24 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ лечения собак, больных дилатационной кардиомиопатией, осложненной застойной сердечной недостаточностью
WO2022073954A1 (en) 2020-10-08 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan in the anaesthesia of non-human mammals
CN113804793B (zh) * 2021-09-24 2023-10-31 青岛欧博方医药科技有限公司 匹莫苯丹软咀嚼剂型的杂质检测方法

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1045031A (en) 1963-04-30 1966-10-05 Iwao Kawakami Dentifrice
US3574859A (en) 1968-07-05 1971-04-13 Carl M Kosti Process for the treatment of hypertrophied gums
US3822349A (en) 1969-06-02 1974-07-02 C Kosti Vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
CA950833A (en) 1971-02-02 1974-07-09 Carl M. Kosti Composition for the treatment of hypertrophied oral tissue
GB1338169A (en) 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
US3832460A (en) 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
US3839522A (en) 1971-08-02 1974-10-01 Batley Janss Enterprises Process for the manufacture of dog bedding
CH630808A5 (en) 1976-05-08 1982-07-15 Uscio Heinz D Process for aromatising pharmaceutical preparations for veterinary medicine
GB1565966A (en) 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
ES482789A0 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
DE2841668A1 (de) 1978-09-25 1980-04-10 Bayer Ag Medikiertes tierfutter auf basis lebermehl
US4256743A (en) 1979-02-22 1981-03-17 President And Fellows Of Harvard College Inhibition of bone resorption with H1 -blocking antihistamines
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4293557A (en) 1979-07-03 1981-10-06 Teikoku Hormone Mfg. Co., Ltd. Antiulcer phenoxypropylamine derivatives
US4375547A (en) 1980-10-02 1983-03-01 Eli Lilly And Company N-Methyl-N'-2-([(2-dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine
IT1209431B (it) 1980-11-28 1989-07-16 Angeli Inst Spa Imidazolilfenil amidine, processi per la loro preparazione e loro impiego farmaceutico, ed intermedi di preparazione.
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
US4704284A (en) 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8313217D0 (en) 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
JPS59222406A (ja) 1983-06-01 1984-12-14 Teijin Ltd 歯周疾患治療用製剤及びその製造法
US4732915A (en) 1983-11-02 1988-03-22 Alza Corporation Process for increasing solubility of drug
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8400863D0 (en) 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
DE3677316D1 (de) 1985-10-17 1991-03-07 Smith Kline French Lab 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate.
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
JPH0759496B2 (ja) 1986-03-25 1995-06-28 ロ−ト製薬株式会社 歯周病治療剤
JPS62223112A (ja) 1986-03-25 1987-10-01 Rooto Seiyaku Kk 歯周病治療剤
IT1204901B (it) 1986-06-25 1989-03-10 Iscofar Sas Composizioni contenenti acido usnico o suoi derivati atte all'impiego nel trattamento della carie dentaria
ZA878182B (en) 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
US4868182A (en) 1986-11-05 1989-09-19 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3728244A1 (de) 1987-08-25 1989-03-09 Thomae Gmbh Dr K Neue (-)-benzimidazole, deren herstellung und diese verbindungen enthaltende arzneimittel
EP0306846A3 (de) 1987-09-11 1990-05-02 Dr. Karl Thomae GmbH Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
SE8704436D0 (sv) 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DE3804490A1 (de) 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
ES2058503T5 (es) 1988-03-29 1999-04-16 Univ Florida Formulaciones farmaceuticas para uso parenteral.
IE62095B1 (en) 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
EP0349657A1 (en) 1988-06-06 1990-01-10 Carl Richard Thornfeldt Manufacture of a medicament for the treatment of teething and colic
GB8824458D0 (en) 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
US5364646A (en) 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
DE4001622A1 (de) 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
DE4001623A1 (de) 1990-01-20 1991-07-25 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen geeigneten arzneimittels
US5188836A (en) 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
JPH0489428A (ja) 1990-07-30 1992-03-23 Kao Corp 多形核白血球活性化剤
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
JPH0570612A (ja) 1991-09-12 1993-03-23 Toyobo Co Ltd 二軸配向ポリエステルフイルム
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
WO1995031963A1 (en) 1994-05-20 1995-11-30 Janssen Pharmaceutica N.V. Chewable flubendazole tablets for companion animals
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
JPH11228302A (ja) 1998-02-18 1999-08-24 Taisho Technos Co Ltd 抗菌防黴組成物
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
JP2002523475A (ja) 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
CA2347939C (en) 1998-10-23 2006-10-10 Akira Matsumori Composition for the treatment of rheumatism, hepatitis or pancreatitis
FR2790668B1 (fr) 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
JP2002544220A (ja) 1999-05-17 2002-12-24 デー.ベー.エフ. 植物物質を含有する顆粒及びその製造方法
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
GB2356346A (en) 1999-11-19 2001-05-23 Mars Uk Ltd Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product
US7105572B2 (en) 2000-02-04 2006-09-12 Takeda Pharmaceutical Company Limited Stable emulsion compositions
US7727548B2 (en) 2000-03-01 2010-06-01 Eisai R&D Management Co., Ltd. Rapidly disintegrable tablet containing polyvinyl alcohol
JP5026630B2 (ja) 2000-03-31 2012-09-12 小林製薬株式会社 造粒粉体及びその製造方法及び圧縮成形固形物
WO2001097861A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
IL153705A0 (en) 2000-06-27 2003-07-06 Vectura Ltd Method of making particles for use in a pharmaceutical composition
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
CN1461218A (zh) 2000-12-18 2003-12-10 诺瓦提斯公司 阿洛地平和贝那普利的治疗组合
EP1247456A3 (en) 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
HUP0303484A2 (hu) 2001-03-02 2004-01-28 Bristol-Myers Squibb Company Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények
ATE481497T1 (de) 2001-08-01 2010-10-15 Univ Utah Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
MXPA04008173A (es) 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
CO5400144A1 (es) 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
PE20040468A1 (es) 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
PL374198A1 (en) 2002-05-23 2005-10-03 Pfizer Inc. Novel combination
SI21223A (sl) 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US20040037869A1 (en) 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
KR20050070036A (ko) 2002-10-07 2005-07-05 아티젼 쎄라퓨틱스, 인크. L형 칼슘 채널을 차단하는 동시에 3형포스포디에스테라제의 활성을 억제할 수 있는디히드로피리딘 화합물
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
WO2004050657A2 (en) 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
EP1575563B1 (en) * 2002-12-19 2007-02-14 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
MXPA05006975A (es) 2002-12-23 2005-12-14 Artesian Therapeutics Inc Compuestos cardiotonicos con actividad inhibidora en contra de receptores beta-adrenergicos y fosfodiesterasa.
US20050085446A1 (en) 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
WO2005035505A2 (en) 2003-09-30 2005-04-21 Artesian Therapeutics, Inc. Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
JP2005281283A (ja) 2004-03-31 2005-10-13 Akira Matsumori ベンズイミダゾール系薬剤の併用医薬
CN1980574A (zh) 2004-05-06 2007-06-13 锡德克斯公司 包含舍曲林和磺基烷基醚环糊精的掩味的制剂
FI20040675A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
EA013632B1 (ru) * 2004-06-28 2010-06-30 Лайфсайкл Фарма А/С Пористые таблетки в качестве носителей для жидких композиций
NZ534939A (en) 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
WO2006060127A2 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
WO2006060122A2 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
CN1702243A (zh) 2005-05-31 2005-11-30 刘坚雄 无壁板框架结构装配组合式房屋建筑及其建造方法
JPWO2006134877A1 (ja) 2005-06-13 2009-01-08 武田薬品工業株式会社 注射剤
US20090149434A1 (en) 2005-09-29 2009-06-11 Joseph Podolski Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
ES2631879T3 (es) 2005-11-14 2017-09-05 Boehringer Ingelheim Vetmedica Gmbh Uso de pimobendano para el tratamiento de la insuficiencia cardíaca asintomática (oculta)
ES2276627B1 (es) 2005-12-02 2008-04-16 Bsh Electrodomesticos España, S.A. Tambor de lavadora.
JP4572300B2 (ja) * 2006-01-19 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
US20070184110A1 (en) 2006-02-09 2007-08-09 Minutza Leibovici Dipyridamole extended-release formulations and process for preparing same
CN101410012A (zh) 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的非甾体抗炎药和β-环糊精的制剂
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
JP5227569B2 (ja) 2007-11-09 2013-07-03 東京インキ株式会社 微粒子乾式コーティング製剤
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
EP2106786A1 (de) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
FR2934156B1 (fr) 2008-07-23 2010-09-24 Virbac Medicament appetissant a administration orale sous forme solide
WO2010055119A2 (en) 2008-11-17 2010-05-20 Novartis Ag Pharmaceutical composition comprising pimobendan
PL2370070T3 (pl) 2008-11-25 2014-02-28 Boehringer Ingelheim Vetmedica Gmbh Pimobendan do zastosowania w leczeniu kardiomiopatii przerostowej u kotów
WO2010078429A1 (en) 2008-12-30 2010-07-08 Impax Laboratories, Inc. Pharmaceutical dosage forms and methods of manufacturing same
GB0912646D0 (en) 2009-07-21 2009-08-26 Jagotec Ag Improvements in or relating to organic compounds
CN102264372B (zh) 2009-08-31 2012-07-11 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
WO2011042463A2 (en) 2009-10-07 2011-04-14 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
NL1037569C2 (en) 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
EP2338480A1 (en) * 2009-12-22 2011-06-29 LEK Pharmaceuticals d.d. Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt
EP2380604A1 (en) 2010-04-19 2011-10-26 InnoRa Gmbh Improved coating formulations for scoring or cutting balloon catheters
JP5813391B2 (ja) * 2011-06-24 2015-11-17 日東電工株式会社 粒子製剤の製造方法
CN102805733B (zh) 2011-06-01 2016-03-09 日东电工株式会社 颗粒制剂及其制造方法
CN103796638A (zh) 2011-08-12 2014-05-14 勃林格殷格翰动物保健有限公司 遮味药物组合物
AU2012101682B4 (en) 2011-11-20 2013-10-24 Betrola Investments Pty Limited Formulation
CN104010632B (zh) * 2011-12-21 2016-08-24 瑞士诺华动物保健有限公司 双层片剂形式的贝那普利和匹莫苯的固定剂量组合
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
GB201207886D0 (en) 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
NZ724002A (en) 2012-05-18 2017-07-28 Luoda Pharma Pty Ltd Liquid formulation comprising propylene glycol and an ace inhibitor
FR3002736B1 (fr) 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
HUE054186T2 (hu) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
KR102308973B1 (ko) 2013-12-04 2021-10-08 베링거잉겔하임베트메디카게엠베하 개선된 피모벤단의 약제학적 조성물
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Also Published As

Publication number Publication date
HUE032347T2 (en) 2017-09-28
BR112016011111A2 (da) 2017-08-08
MX2016007134A (es) 2016-09-08
ES2883448T3 (es) 2021-12-07
EA201600438A1 (ru) 2016-11-30
HUE056143T2 (hu) 2024-01-28
KR102308973B1 (ko) 2021-10-08
EP2925305B1 (en) 2016-07-27
BR112016011111B1 (pt) 2022-11-16
DK2925305T3 (da) 2016-10-10
AU2017203887B2 (en) 2018-10-25
JP5905999B2 (ja) 2016-04-20
US10874620B2 (en) 2020-12-29
US10172804B2 (en) 2019-01-08
EP2925305A1 (en) 2015-10-07
EP3106150B1 (en) 2021-07-28
AU2014359427B2 (en) 2017-04-20
CA2930033A1 (en) 2015-06-11
CA3176466A1 (en) 2015-06-11
WO2015082389A1 (en) 2015-06-11
CN105813633B (zh) 2020-01-31
CA2930033C (en) 2022-12-13
JP2016505064A (ja) 2016-02-18
JP6506711B2 (ja) 2019-04-24
CN105813633A (zh) 2016-07-27
BR122019024673B1 (pt) 2023-04-11
KR20160089525A (ko) 2016-07-27
PL3106150T3 (pl) 2022-01-03
US20190083411A1 (en) 2019-03-21
US11298325B2 (en) 2022-04-12
AU2017203887A1 (en) 2017-06-29
US20220183987A1 (en) 2022-06-16
EA201992230A1 (ru) 2020-02-28
EA034054B1 (ru) 2019-12-23
US20210059950A1 (en) 2021-03-04
EP3106150A1 (en) 2016-12-21
US20190083410A1 (en) 2019-03-21
PL2925305T3 (pl) 2017-07-31
JP2019123737A (ja) 2019-07-25
JP2016108346A (ja) 2016-06-20
US10653633B2 (en) 2020-05-19
ES2593210T3 (es) 2016-12-07
CN110721164A (zh) 2020-01-24
AU2014359427A1 (en) 2016-05-05
US20150150820A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
SMT201700094B (it) Composto di pirazina carbossammide
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK2845905T3 (da) Fremstilling af oligosaccharider
DK2968529T3 (da) Fremstilling af jordnøddeformuleringer til oral desensibilisering
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK2961388T3 (da) Kombinationer af lægemidler
DK2961766T3 (da) Kvantificering af vaccinesammensætninger
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
DK3022217T3 (da) Sammensætninger til modulering af tau-ekspression
DK2984166T3 (da) Sammensætninger til behandling af mpsi
DK3456831T3 (da) Målrettet modifikation af rottegenom
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3725778T3 (da) Formuleringer af enzalutamid
DK2958900T3 (da) 2-aminopyrimidinderivater til behandling af virusinfektioner
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
DK2968208T3 (da) Behandling af kataplexi
DK3027618T3 (da) Polymorf af syk-hæmmere
DK3454346T3 (da) Anordning til cylotronfremstilling af technetium-99m
DK3157508T3 (da) Fast oral doseringsform af lipofile forbindelser
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK2970954T3 (da) Modifikation af polypeptider
DK2970389T3 (da) Farmaceutiske forbindelser
DK2968214T3 (da) Hidtil ukendte analgetiske sammensætninger
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib